Elan's Response to FASB
While the Federal Accounting Standards Board has basically ruled out the kinds of limited partnerships Elan for years used to finance its R&D off its income statement, a new set of deals show just how Elan is using deals with biotechs and other drug delivery companies to both supplement its research program and spare its P&L.
You may also be interested in...
Autobio’s test reportedly only correctly identified half the positive COVID-19 samples in an NIH evaluation.
Benefits of OTC monograph reform legislation passed in March likely will take at least several years, according to GAO report to Congress. It notes the FDA still is analyzing the legislation and it may need two years to add and train staff.
A team led by Dalhousie University researchers examined 174 novel approvals from 2011-2015 and found 155 instances of disagreement, affecting 42 drugs.